Quavonlimab
Quavonlimab (MK-1308) is a novel anti-CTLA-4 antibody[1].
Product Specifications
CAS Number
[2254059-25-9]
Product Name Alternative
MK-1308
UNSPSC
12352203
Target
CTLA-4
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/quavonlimab.html
Purity
99.0
Solubility
10 mM in DMSO
Smiles
[Quavonlimab]
Molecular Weight
(144.24 kDa)
References & Citations
[1]Perets R, et al. Safety and efficacy of quavonlimab, a novel anti-CTLA-4 antibody (MK-1308), in combination with pembrolizumab in first-line advanced non-small-cell lung cancer. Ann Oncol. 2021;32 (3) :395-403.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 2
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
208431 100 µg
SRCAP (aa309-322) (Domino homolog 1, Domino homolog 2, DOMO1, EAF1, FLJ44499, Helicase SRCAP, KIAA0309, OTTHUMP00000208671, Snf2-related CBP activator protein, Snf2-related CREBBP activator protein, Swi2/Snf2-related ATPase homolog, Domino homolog 1, SWR1)
Ask
View Details